Tsingke Biotech and iGeneTech Bioscience Form Strategic Partnership to Accelerate Synthetic Biology Innovation

Beijing, China – Tsingke Biotech Co., Ltd. ("Tsingke Biotech") and iGeneTech Bioscience (Beijing) Co., Ltd. ("iGeneTech") have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together the strengths of both companies to drive innovation, streamline product development, and expand market reach.

The partnership was formalized at a signing ceremony held at Tsingke Biotech’s Beijing headquarter, where both companies expressed their shared commitment to revolutionizing synthetic biology in response to the growing needs of the market.

Image: The Partnership Signing Ceremony Between Tsingke Biotech and iGeneTech Bioscience

Harnessing Expertise to Transform the Industry

Synthetic biology is rapidly emerging as a transformative field with wide-reaching applications, including precision medicine, bio-breeding, and gene editing. At the core of these advancements are high-throughput and column-based synthesis, which Tsingke Biotech and iGeneTech aim to further develop.

Tsingke Biotech, a leader in gene synthesis, has developed a fully integrated industrial chain that spans raw materials, equipment, process design, AI, and digital technologies. Known for its scalability, standardization, and stability, the company’s cutting-edge technology includes column synthesis and an intelligent factory-driven production system that supports from small-scale laboratory production (2nmol) to large-scale industrial synthesis (12mmol). Their gene synthesis services include:

● Primer Synthesis (<300nt)

● Gene Synthesis (300bp–5kb)

● Long Gene Synthesis (>5kb)

On the other hand, iGeneTech contributes its proprietary Ignite 3.0 high-throughput synthesis platform. With its ability to process oligo pools ranging from 4k to 650k in size and achieve synthesis lengths up to 200nt with error rates as low as 0.2%, this platform addresses key challenges around throughput, speed, and cost.

A Shared Vision for Growth

“We are excited to partner with iGeneTech, whose expertise in gene capture and next-generation sequencing (NGS) technology enhances our strengths in gene synthesis,” said Mr. Shijin Ma, CEO of Tsingke Biotech. “This partnership will speed up the translation of technological